Galmed Pharmaceuticals (GLMD)

Executive Summary

Galmed Pharmaceuticals is a clinical-stage Israeli biotech focused on developing oral small molecule therapies for liver and inflammatory diseases, with lead asset Aramchol, a first-in-class SCD1 modulator in Phase 3 for NASH and fibrosis. Despite a challenging NASH landscape, Aramchol's unique mechanism and prior Phase 2b data showing fibrosis improvement support its potential. The company also has a preclinical candidate Amilo-5MER targeting upstream inflammatory pathways. With a low market cap (~$3.7M) and no approved products, Galmed represents a high-risk, high-reward opportunity that depends heavily on successful Phase 3 outcomes and potential partnership or financing. Key near-term catalysts include Phase 3 interim or top-line data (expected 2027) and potential strategic collaborations to extend cash runway and de-risk development.

Upcoming Catalysts (preview)

• H2 2027Phase 3 ARMOR trial top-line results for Aramchol in NASH30% success
• TBDPotential licensing or partnership deal for Aramchol or Amilo-5MER20% success
• Q3 2026Regulatory or financing update to extend cash runway50% success